Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.

2.50
Hdl Handle:
http://hdl.handle.net/10541/53474
Title:
Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.
Authors:
Slotman, Berend J; Mauer, Murielle E; Bottomley, Andrew; Faivre-Finn, Corinne ( 0000-0001-5617-9781 ) ; Kramer, Gijs; Rankin, Elaine M; Snee, Michael; Hatton, Matthew; Postmus, Pieter E; Collette, Laurence; Senan, Suresh
Abstract:
PURPOSE: Prophylactic cranial irradiation (PCI) in patients with extensive-disease small-cell lung cancer (ED-SCLC) leads to significantly fewer symptomatic brain metastases and improved survival. Detailed effects of PCI on health-related quality of life (HRQOL) are reported here. PATIENTS AND METHODS: Patients (age, 18 to 75 years; WHO < or = 2) with ED-SCLC, and any response to chemotherapy, were randomly assigned to either observation or PCI. Health-related quality of life (HRQOL) and patient-reported symptoms were secondary end points. The European Organisation for the Research and Treatment of Cancer core HRQOL tool (Quality of Life Questionnaire C30) and brain module (Quality of Life Questionnaire Brain Cancer Module) were used to collect self-reported patient data. Six HRQOL scales were selected as primary HRQOL end points: global health status; hair loss; fatigue; and role, cognitive and emotional functioning. Assessments were performed at random assignment, 6 weeks, 3 months, and then 3-monthly up to 1 year and 6-monthly thereafter. RESULTS: Compliance with the HRQOL assessment was 93.7% at baseline and dropped to 60% at 6 weeks. Short-term results up to 3 months showed that there was a negative impact of PCI on selected HRQOL scales. The largest mean difference between the two arms was observed for fatigue and hair loss. The impact of PCI on global health status as well as on functioning scores was more limited. For global health status, the observed mean difference was eight points on a scale 0 to 100 at 6 weeks (P = .018) and 3 months (P = .055). CONCLUSION: PCI should be offered to all responding ED SCLC patients. Patients should be informed of the potential adverse effects from PCI. Clinicians should be alert to these; monitor their patients; and offer appropriate support, clinical, and psychosocial care.
Affiliation:
Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Citation:
Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. 2009, 27 (1):78-84 J. Clin. Oncol.
Journal:
Journal of Clinical Oncology
Issue Date:
1-Jan-2009
URI:
http://hdl.handle.net/10541/53474
DOI:
10.1200/JCO.2008.17.0746
PubMed ID:
19047288
Type:
Article
Language:
en
ISSN:
1527-7755
Appears in Collections:
All Christie Publications ; Clinical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorSlotman, Berend J-
dc.contributor.authorMauer, Murielle E-
dc.contributor.authorBottomley, Andrew-
dc.contributor.authorFaivre-Finn, Corinne-
dc.contributor.authorKramer, Gijs-
dc.contributor.authorRankin, Elaine M-
dc.contributor.authorSnee, Michael-
dc.contributor.authorHatton, Matthew-
dc.contributor.authorPostmus, Pieter E-
dc.contributor.authorCollette, Laurence-
dc.contributor.authorSenan, Suresh-
dc.date.accessioned2009-03-09T16:34:00Z-
dc.date.available2009-03-09T16:34:00Z-
dc.date.issued2009-01-01-
dc.identifier.citationProphylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. 2009, 27 (1):78-84 J. Clin. Oncol.en
dc.identifier.issn1527-7755-
dc.identifier.pmid19047288-
dc.identifier.doi10.1200/JCO.2008.17.0746-
dc.identifier.urihttp://hdl.handle.net/10541/53474-
dc.description.abstractPURPOSE: Prophylactic cranial irradiation (PCI) in patients with extensive-disease small-cell lung cancer (ED-SCLC) leads to significantly fewer symptomatic brain metastases and improved survival. Detailed effects of PCI on health-related quality of life (HRQOL) are reported here. PATIENTS AND METHODS: Patients (age, 18 to 75 years; WHO < or = 2) with ED-SCLC, and any response to chemotherapy, were randomly assigned to either observation or PCI. Health-related quality of life (HRQOL) and patient-reported symptoms were secondary end points. The European Organisation for the Research and Treatment of Cancer core HRQOL tool (Quality of Life Questionnaire C30) and brain module (Quality of Life Questionnaire Brain Cancer Module) were used to collect self-reported patient data. Six HRQOL scales were selected as primary HRQOL end points: global health status; hair loss; fatigue; and role, cognitive and emotional functioning. Assessments were performed at random assignment, 6 weeks, 3 months, and then 3-monthly up to 1 year and 6-monthly thereafter. RESULTS: Compliance with the HRQOL assessment was 93.7% at baseline and dropped to 60% at 6 weeks. Short-term results up to 3 months showed that there was a negative impact of PCI on selected HRQOL scales. The largest mean difference between the two arms was observed for fatigue and hair loss. The impact of PCI on global health status as well as on functioning scores was more limited. For global health status, the observed mean difference was eight points on a scale 0 to 100 at 6 weeks (P = .018) and 3 months (P = .055). CONCLUSION: PCI should be offered to all responding ED SCLC patients. Patients should be informed of the potential adverse effects from PCI. Clinicians should be alert to these; monitor their patients; and offer appropriate support, clinical, and psychosocial care.en
dc.language.isoenen
dc.subjectSmall-Cell Lung Canceren
dc.subjectRandomized Controlled Trialen
dc.subjectLung Canceren
dc.subjectRandomized Clinical Trial-
dc.subject.meshCranial Irradiation-
dc.subject.meshLung Neoplasms-
dc.subject.meshQuality of Life-
dc.subject.meshSmall Cell Lung Carcinoma-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms/psychology-
dc.subject.meshLung Neoplasms/radiotherapy*-
dc.titleProphylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.en
dc.identifier.journalJournal of Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.